Castle Biosciences Inc
NASDAQ:CSTL
Net Margin
Castle Biosciences Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Castle Biosciences Inc
NASDAQ:CSTL
|
576.7m USD |
-3%
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
90.1B USD |
1%
|
|
| US |
|
Cigna Corp
NYSE:CI
|
81.2B USD |
2%
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
67.9B EUR |
2%
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
26.5B EUR |
5%
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
25.2B EUR |
3%
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.9B USD |
6%
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
20.6B USD |
9%
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
12.7B EUR |
3%
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.2B USD |
6%
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
9.5B USD |
10%
|
Castle Biosciences Inc
Glance View
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Castle Biosciences Inc's most recent financial statements, the company has Net Margin of -2.7%.
You don't have any saved screeners yet